Atria Wealth Solutions Inc. Buys 2,674 Shares of DexCom, Inc. (NASDAQ:DXCM)

Atria Wealth Solutions Inc. lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 73.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 6,290 shares of the medical device company’s stock after buying an additional 2,674 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in DexCom were worth $781,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Valley National Advisers Inc. boosted its holdings in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the period. MV Capital Management Inc. boosted its stake in DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares during the period. Washington Trust Advisors Inc. grew its holdings in DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after buying an additional 193 shares in the last quarter. Turtle Creek Wealth Advisors LLC bought a new position in DexCom during the 4th quarter worth $57,000. Finally, NBC Securities Inc. bought a new position in DexCom during the 3rd quarter worth $47,000. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on DXCM shares. UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Royal Bank of Canada initiated coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price on the stock. Citigroup lifted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group increased their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Finally, Raymond James lifted their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $141.67.

DexCom Stock Up 1.4 %

Shares of NASDAQ DXCM opened at $128.37 on Friday. The stock has a 50-day moving average price of $132.11 and a two-hundred day moving average price of $119.96. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The company has a market cap of $51.05 billion, a price-to-earnings ratio of 82.82, a PEG ratio of 2.15 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. As a group, analysts forecast that DexCom, Inc. will post 1.77 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In related news, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, COO Jacob Steven Leach sold 14,639 shares of DexCom stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the transaction, the chief operating officer now owns 273,913 shares in the company, valued at $36,816,646.33. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at $8,304,405.66. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 190,004 shares of company stock worth $25,610,270. Corporate insiders own 0.41% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.